Advanced in Prostate Cancer

Mark A. Sidhom

Sydney, NSW, AU 
Advanced in Prostate Cancer
Sydney, NSW, AU 
OverviewLocationsClinical Research

Overview

Mark Sidhom practices in Sydney, Australia. Mr. Sidhom is rated as an Advanced expert by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Muscle Invasive Bladder Cancer, Renal Cell Carcinoma (RCC), Bladder Cancer, and Prostatectomy.

His clinical research consists of co-authoring 57 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 37 articles and participated in 2 clinical trials in the study of Prostate Cancer.

Gender
Male

Locations

Sydney, NSW, Australia
Other Locations
Liverpool, NSW, Australia
NSW, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Randomised Phase 3 Trial of Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer: ENZARAD
Randomised Phase 3 Trial of Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer: ENZARAD
Enrollment Status: Active_not_recruiting
Publish Date: May 30, 2025
Intervention Type: Drug, Radiation
Study Drugs: Enzalutamide, Conventional NSAA, LHRHA
Study Phase: Phase 3
Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer
Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: January 27, 2025
Intervention Type: Drug, Radiation
Study Drugs: Pembrolizumab, Cisplatin
Study Phase: Phase 2
DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801): A Randomised Phase 3 Double-blind, Placebo-controlled Trial of Adding Darolutamide to Androgen Deprivation Therapy and Definitive or Salvage Radiation in Very High Risk, Clinically Localised Prostate Cancer
DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801): A Randomised Phase 3 Double-blind, Placebo-controlled Trial of Adding Darolutamide to Androgen Deprivation Therapy and Definitive or Salvage Radiation in Very High Risk, Clinically Localised Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2023
Intervention Type: Radiation, Drug
Study Drugs: Darolutamide, Luteinizing Hormone-Releasing Hormone Analog
Study Phase: Phase 3
View 2 Less Clinical Trials

57 Total Publications

Dosimetric Clues to Addressing Urinary Toxicity Following Stereotactic Prostate Radiation Therapy.
Dosimetric Clues to Addressing Urinary Toxicity Following Stereotactic Prostate Radiation Therapy.
Journal: Advances in radiation oncology
Published: May 14, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Sidhom's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile